DNA Methylation Market is expected to reach US$ 5815.49 Million by 2033

The global DNA Methylation Market is expected to generate a market value of US$ 1437.5 Million in 2023 and a market value of US$ 5815.49 Million by 2033, with a CAGR of 15% from 2023 to 2033. The increasing number of cancer cases worldwide remains the primary driver of the DNA methylation market's expected growth. In the historical period 2016 to 2021, the market for DNA methylation grew at a CAGR of 11%.

To learn more about this report @ https://www.futuremarketinsights.com/reports/dna-methylation-market

The significant increase in the adoption of epigenetics-based treatment strategies, coupled with the broad nucleic acid-based diagnostic tests kits commercialization is projected to drive the growth of the market. In May 2022, an article published in PubMed stated that the epigenetics-based treatment strategies are to be used for studying Alzheimer’s disease.

Moreover, Key players operating in the market are taking several initiatives such as new product developments, entering into a strategic alliance, and regional expansion among others. All these factors are positively influencing the demand for DNA methylation market.

Key Takeaways from the Market Study

By technology, sequencing is expected to possess 35% market share for DNA methylation market in 2023.
By product, consumables are expected to possess 35% market share for DNA methylation market in 2023.
By application, clinical research is expected to possess 40% market share for DNA methylation market in 2023.
By application, diagnostic segment is anticipated to witness the fastest growth in the coming years with a CAGR of 16%.
By end use, pharmaceutical and biotechnology end-use segment are expected to possess 42% market share for DNA methylation in 2023.
North America is expected to possess 40% market share for DNA methylation market in 2023.
Asia Pacific is expected to possess 38% market share for DNA methylation market in 2023.

“Expenditure on research and development along with government funding is expected to accelerate the growth of DNA methylation market.” comments a Future Market Insights analyst.

Competitive Landscape

Some prominent players in the global DNA methylation market include New England Biolabs, Sysmex Corporation, Abcam plc., F. Hoffmann-La Roche Ltd., Diagenode Diagnostics S.A., Thermo-Fisher Scientific Inc., Agilent Technologies Inc., BioRad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Active Motif, Inc., Illumina Inc.,EpiGentek Group Inc., Pacific Biosciences Inc., New England Biolabs Inc., Merck KGaA, Zymo Research Corporation, PerkinElmer Inc.

In May 2022, Oxford Nanopore announced integrating Remora, a technique that offers accurate and real-time epigenetic insights with nanopore sequencing software. This would further offer simple access to accurate whole genome methylation detection.
In June 2020, Base Genomics announced of advancing and developing its DNA methylation technology. the aim is to sequence a large amount of epigenetic data from a blood test which could revolutionize the preventative medicine arena.

Key Segments Profiled in the DNA Methylation Industry Survey

Technology: